Payment overview · 2025
General Payments
$155.09
8 reported records · 8 companies
Healthcare provider profile · identity verified
Hemalatha Murugan
Allopathic & Osteopathic Physicians|Family Medicine · ONTARIO, CA · NPI 1124681580
Verified facts
What the public records show
CMS Open Payments records show Hemalatha Murugan received $155.09 in general payments during 2025 across 8 reported records.
Neurocrine BioSciences, Inc. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $31.23 | 20.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.22 | 15.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.80 | 12.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.27 | 12.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.11 | 11.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.05 | 10.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.34 | 9.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.07 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $155.09 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $31.23 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 198 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 22 |
| Levetiracetam | Levetiracetam | 132 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 28 |
| Metformin Hcl | Metformin Hcl | 123 | 20 |
| Potassium Chloride | Potassium Chloride | 107 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 106 | 13 |
| Famotidine | Famotidine | 104 | 19 |
| Donepezil Hcl | Donepezil Hcl | 100 | 13 |
| Furosemide | Furosemide | 99 | 19 |
| Memantine Hcl | Memantine Hcl | 98 | suppressed |
| Eliquis | Apixaban | 97 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 18 |
| Gabapentin | Gabapentin | 84 | 23 |
| Losartan Potassium | Losartan Potassium | 82 | 16 |
| Lisinopril | Lisinopril | 81 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 74 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Omeprazole | Omeprazole | 67 | suppressed |
| Pregabalin | Pregabalin | 55 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 53 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 51 | 17 |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Lorazepam | Lorazepam | 47 | 16 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Humulin R | Insulin Regular, Human | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Humalog | Insulin Lispro | 38 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | 11 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 26 |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 34 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Procrit | Epoetin Alfa | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | 11 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 14 |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.09 · 8 records | Neurocrine BioSciences, Inc. | ABRYSVO, CAPLYTA, COMIRNATY, FANAPT, INGREZZA, PREVNAR 20, REXULTI, TONMYA, TRELEGY ELLIPTA, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error